Your AI-Trained Oncology Knowledge Connection!
Nivolumab Monotherapy, With Ipilimumab Continuously Improves Outcomes in Advanced Melanoma
Progression-free survival more than doubled when relatlimab was added to nivolumab to treated patients with previously untreated, unresectable or metastatic melanoma.
The study concluded that immune-related adverse events were more common than previously anticipated following adjuvant anti–PD-1 therapy and persisted with prolonged follow-up.
Darovasertib as monotherapy for the treatment for patients with heavily pretreated metastatic uveal melanoma induced responses and promising rates of overall survival, according to preliminary data from a phase 1/2 trial.
Lifileucel (LN-144), the tumor-infiltrating lymphocyte therapy, showed a positive objective response rate with the median duration of response not yet reached after more than 28 months of follow-up in patients with advanced melanoma.
These data establish pembrolizumab as a promising treatment option for those with locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma, according to Brett G.M. Hughes, MD.
The combination adjuvant treatment of ipilimumab plus nivolumab did not meet the dual primary endpoints of the phase 3 CheckMate-915 trial, failing to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations.
Frontline treatment with tebentafusp significantly improved overall survival in patients with metastatic uveal melanoma, according to data from the phase 3 IMCgp100-202 trial.
When compared against nivolumab alone, relatlimab plus nivolumab delayed progression in patients with unresectable stage III and IV untreated melanoma.
Adjuvant immunotherapy treatment was associated with a significant survival benefit for patients with stage II melanoma in a study presented at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care.
First-line treatment with nivolumab plus ipilimumab showed a moderate improvement in overall survival and a manageable safety profile in patients with metastatic uveal melanoma.
The PD-1 inhibitor cemiplimab was granted approval in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom these therapies are not appropriate.
During the age of systemic immunotherapy, investigators observed a change in the incidence of second primary cancers after metastatic melanoma that included solid tumor and hematologic malignancies.
The novel viral immunotherapy PVSRIPO is designed to stimulate a patient’s innate and adaptive immune system to promote an antitumor response and establish long-term immunologic memory to help keep their cancer at bay.
A study published in JAMA Dermatology found changes in diagnostics and awareness may, in part, account for initial increases in incidence rates for Merkel cell carcinoma.
The clinical trial of tebentafusp (IMCgp100) versus investigator’s choice in metastatic uveal melanoma met its pre-defined boundaries for statistical significance of the primary end point of overall survival in its first pre-planned interim analysis.
Study investigators indicated that these results call for the need to revise skin cancer health policies to be able to handle the increasing burden of keratinocyte carcinoma management.
Adil Daud, MD, spoke about the emergence of next-generation sequencing and the importance of testing patients with melanoma for BRAF mutations.
Jeffrey Weber, MD, PhD, discusses the unmet needs professionals take into consideration when deciding treatment options for patients with melanoma.
Data from the COMBI-AD Trial evaluating dabrafenib and trametinib to treat melanoma was analyzed by Hussein Tawbi, MD, PhD, of The University of Texas MD Anderson Cancer Center.
CancerNetwork spoke with Jason Luke, MD, FACP, at the SMR Conference regarding the latest updates on melanoma.
“The data reported, in addition to its ease of use, demonstrate the potential of [tavokinogene telseplasmid] in combination with pembrolizumab as a next-generation intratumoral IL-12 therapy that can induce regression of both locally treated and untreated distant and visceral lesions,” said Paolo A. Ascierto, MD.
Results from this study suggest that this combination is active and should be considered for this patient population, though additional research is still necessary.
Pretreatment circulating tumor DNA was found to be a reliable indicator of patient outcome for those with metastatic melanoma in the first-line immune checkpoint inhibitor (ICI) treatment setting, but not in the second-line setting.
A study published in JAMA Dermatology determined that topical immunosuppressant medications used to treat adult patients with atopic dermatitis do not increase the risk of common forms of cancer despite warning labels on the packaging.
The study is evaluating the nivolumab-ipilimumab combination versus nivolumab alone in patients who have had a complete surgical removal of stage IIIb/c/d or stave IV melanoma.
